MarketCap
Facebook
X
Telegram
Orgenesis Retained Earnings | ORGS
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -225 M | -177 M | -121 M | -106 M | -88.3 M | -89.4 M | -62.4 M | -44.1 M | -29.8 M | -20.6 M | -16.2 M | -10.7 M | -5.14 M | -138 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -138 K | -225 M | -71.1 M |
Quarterly Retained Earnings Orgenesis
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -177 M | -204 M | -195 M | -186 M | -177 M | -142 M | -130 M | -125 M | -121 M | -117 M | -116 M | -110 M | -106 M | -101 M | -91.2 M | -88.5 M | -88.3 M | -88.3 M | -88.3 M | -88.3 M | -89.4 M | -89.4 M | -89.4 M | -89.4 M | -65.2 M | -62.4 M | -62.4 M | -65.2 M | -44.1 M | -44.1 M | -44.1 M | -44.1 M | -31.8 M | -29.8 M | -29.8 M | -29.8 M | -20.6 M | -20.6 K | -20.6 K | -20.6 K | -16.2 M | -16.2 M | -16.2 M | -16.2 M | -10.7 M | -10.7 M | -10.7 M | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -20.6 K | -204 M | -76 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
-917 M | $ 4.2 | -0.36 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
-15.5 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-211 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-105 M | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
-260 M | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
937 M | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-118 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
16.9 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.09 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
-418 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-3.49 B | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
-25.1 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Codiak BioSciences
CDAK
|
-325 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
646 M | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
169 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
-695 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-401 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
-2.97 B | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
-467 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-930 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-501 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
-739 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
24.5 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-321 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
-453 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-1.42 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
-151 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
-510 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
-439 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-675 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
-253 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
-1.81 B | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
7.22 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-125 M | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
-150 M | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
-3.76 B | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
-177 M | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-1.95 B | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-159 M | $ 1.66 | -2.64 % | $ 1.12 B | Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
-1.43 B | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
-759 M | - | -23.04 % | $ 26.6 M | USA |
 |
Tyme Technologies
TYME
|
-160 M | - | 8.07 % | $ 54 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Verona Pharma plc
VRNA
|
-562 M | - | - | $ 69.7 B | Britain |